# Surufatinib Plus Camrelizumab and AS in First Line Treatment of Advanced Metastatic Pancreatic Cancer

Source: https://onco.cc/trials/nct05218889/  
OnCo record `nct05218889` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of gemcitabine + nab-paclitaxel in pancreatic cancer, run by Chinese PLA General Hospital, now recruiting.

## Summary

Surufatinib Plus Camrelizumab and AS in First Line Treatment of Advanced Metastatic Pancreatic Cancer is a phase 1/2, randomised interventional study registered as NCT05218889 by Chinese PLA General Hospital, with a registry enrolment figure of 90 participants, started 2021-08-04 and due to reach its primary completion in 2024-12-16. Interventions recorded: surufatinib + camrelizumab + nab-paclitaxel + S-1; nab-paclitaxel + gemcitabine. Conditions listed: Pancreatic Cancer; PDAC - Pancreatic Ductal Adenocarcinoma; Pancreas Cancer; Pancreatic Neoplasms. Primary outcome: DLTs; RP2D; ORR. Pancreatic eligibility wording from the registry: "Patients with histologically or cytologically confirmed unresectable, locally advanced, or metastatic pancreatic ductal adenocarcinoma;". Sites: China. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-24
- Tags: ctgov-ingest; pancreatic-deep-dive
- Registry id: NCT05218889
- Phase: 1/2
- Setting: Surufatinib Plus Camrelizumab and AS in First Line Treatment of Advanced Metastatic Pancreatic Cancer: a Prospective, Randomized Controlled Clinical Trial
- Sponsor: Chinese PLA General Hospital
- Enrolled: 90

## Sources

- ClinicalTrials.gov NCT05218889: https://clinicaltrials.gov/study/NCT05218889

## Connected records

- cancers: [Locally advanced unresectable pancreatic ductal adenocarcinoma](https://onco.cc/cancers/locally-advanced-pdac/), [Metastatic pancreatic ductal adenocarcinoma](https://onco.cc/cancers/metastatic-pdac/)
- technologies: [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/)
- drugs: [Gemcitabine + nab-paclitaxel](https://onco.cc/drugs/gemcitabine-nab-paclitaxel/)
- terms: [Pancreatic cancer trials open today (registry snapshot and UK sites)](https://onco.cc/terms/pancreatic-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct05218889.json